Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, ...(ize composition of theselesions can pote...),Health

Date:9/2/2008

ize composition of these lesions can potentially provide a means to examine the natural history of atherosclerosis. This, combined with studies of novel agents that act directly on the plaque, can help increase our understanding of the mechanisms of future clinical events," commented Patrick Serruys, MD, PhD, Professor of Medicine, the Erasmus University, and Chairman of the Steering Committee for IBIS-2.

IBIS-2 was a 52 week, 300 participant, international, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The main objectives of the study were to determine the effects of darapladib on composition and biomechanical properties of atherosclerotic plaque, as well as circulating inflammatory biomarkers.

"Current treatments for atherosclerosis include preventative lifestyle modifications and the regulation of physiological and biochemical risk factors such as blood pressure and lipid profile. VH(R) IVUS measures the effects of investigational compounds on plaque composition. We believe that IVUS can be an indispensable assessment tool in the development of a drug candidate that directly affects coronary plaque stability, as opposed to treating symptoms or lipid levels alone," said Scott Huennekens, President and CEO, Volcano Corp. "The ability to identify and characterize composition may lead to great advances in CVD drug development, diagnosis, and eventually tailored systemic therapy. The same way a biopsy and other blood and imaging tests can define a cancer treatment plan, we believe that one day Volcano technology could help define a personalized patient by patient strategy for systemic and local therapy that could dramatically improve patient outcomes."

Volcano's VH(R) IVUS technology uses advanced spectral analysis techniques to allow simplified interpretation of ultrasound images and provide detailed information on the composition
'/>"/>

SOURCE Volcano Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
5. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
6. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
7. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
8. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
9. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
10. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
11. GeoVax Reports Progress on Its AIDS Vaccine Technology